肺癌液体活检:纳米流式细胞术检测血液中的非小细胞肺癌。

IF 5.1 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Andong Zhang, Qiqi Gao, Chen Tian, Wentao Chen, Catherine Pan, Ling Wang, Jie Huang, Jing Zhang
{"title":"肺癌液体活检:纳米流式细胞术检测血液中的非小细胞肺癌。","authors":"Andong Zhang, Qiqi Gao, Chen Tian, Wentao Chen, Catherine Pan, Ling Wang, Jie Huang, Jing Zhang","doi":"10.1016/j.labinv.2024.102151","DOIUrl":null,"url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) remains a leading cause of global mortality, with current screening and diagnostic methods often lacking in sensitivity and specificity. In our endeavor to develop precise, objective, and easily accessible diagnostic biomarkers for NSCLC, this study aimed to leverage rapidly evolving liquid biopsy techniques in the field of pathology to differentiate NSCLC patients from healthy controls by isolating peripheral blood samples and enriching extracellular vesicles (EVs) containing lung-derived proteins (TTF-1 and SFTPB), along with the cancer-associated protein CD151<sup>+</sup> EVs. Additionally, for practical applications, we established a nano-flow cytometry assay to detect plasma EVs readily. NSCLC patients demonstrated significantly reduced counts of TTF-1<sup>+</sup> EVs and CD151<sup>+</sup> EVs in plasma compared to healthy controls (P<0.0001), while SFTPB<sup>+</sup> EVs showed no significant difference (P>0.05). Integrated analysis of TTF-1<sup>+</sup>, CD151<sup>+</sup> and SFTPB<sup>+</sup> EVs yielded area under the curve (AUC) values of 0.913 and 0.854 in the discovery and validation cohorts, respectively. Thus, while further validation is essential, the newly developed technologies are of great significance for the robust detection of NSCLC biomarkers.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Liquid Biopsy in Lung Cancer: Nano-Flow Cytometry Detection of Non-Small Cell Lung Cancer in Blood.\",\"authors\":\"Andong Zhang, Qiqi Gao, Chen Tian, Wentao Chen, Catherine Pan, Ling Wang, Jie Huang, Jing Zhang\",\"doi\":\"10.1016/j.labinv.2024.102151\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Non-small cell lung cancer (NSCLC) remains a leading cause of global mortality, with current screening and diagnostic methods often lacking in sensitivity and specificity. In our endeavor to develop precise, objective, and easily accessible diagnostic biomarkers for NSCLC, this study aimed to leverage rapidly evolving liquid biopsy techniques in the field of pathology to differentiate NSCLC patients from healthy controls by isolating peripheral blood samples and enriching extracellular vesicles (EVs) containing lung-derived proteins (TTF-1 and SFTPB), along with the cancer-associated protein CD151<sup>+</sup> EVs. Additionally, for practical applications, we established a nano-flow cytometry assay to detect plasma EVs readily. NSCLC patients demonstrated significantly reduced counts of TTF-1<sup>+</sup> EVs and CD151<sup>+</sup> EVs in plasma compared to healthy controls (P<0.0001), while SFTPB<sup>+</sup> EVs showed no significant difference (P>0.05). Integrated analysis of TTF-1<sup>+</sup>, CD151<sup>+</sup> and SFTPB<sup>+</sup> EVs yielded area under the curve (AUC) values of 0.913 and 0.854 in the discovery and validation cohorts, respectively. Thus, while further validation is essential, the newly developed technologies are of great significance for the robust detection of NSCLC biomarkers.</p>\",\"PeriodicalId\":17930,\"journal\":{\"name\":\"Laboratory Investigation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Laboratory Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.labinv.2024.102151\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.labinv.2024.102151","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

非小细胞肺癌(NSCLC)仍然是导致全球死亡的主要原因,而目前的筛查和诊断方法往往缺乏敏感性和特异性。为了开发精确、客观、易于获得的 NSCLC 诊断生物标志物,本研究旨在利用病理学领域快速发展的液体活检技术,通过分离外周血样本,富集含有肺源性蛋白(TTF-1 和 SFTPB)的细胞外囊泡(EVs)以及癌症相关蛋白 CD151+ EVs,将 NSCLC 患者与健康对照组区分开来。此外,在实际应用中,我们还建立了一种纳米流式细胞术检测方法,可随时检测血浆中的EVs。与健康对照组相比,NSCLC 患者血浆中 TTF-1+ EVs 和 CD151+ EVs 的数量明显减少(P+ EVs 无显著差异(P>0.05))。对TTF-1+、CD151+和SFTPB+ EVs进行综合分析后,发现组和验证组的曲线下面积(AUC)值分别为0.913和0.854。因此,虽然进一步的验证至关重要,但新开发的技术对NSCLC生物标记物的稳健检测意义重大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Liquid Biopsy in Lung Cancer: Nano-Flow Cytometry Detection of Non-Small Cell Lung Cancer in Blood.

Non-small cell lung cancer (NSCLC) remains a leading cause of global mortality, with current screening and diagnostic methods often lacking in sensitivity and specificity. In our endeavor to develop precise, objective, and easily accessible diagnostic biomarkers for NSCLC, this study aimed to leverage rapidly evolving liquid biopsy techniques in the field of pathology to differentiate NSCLC patients from healthy controls by isolating peripheral blood samples and enriching extracellular vesicles (EVs) containing lung-derived proteins (TTF-1 and SFTPB), along with the cancer-associated protein CD151+ EVs. Additionally, for practical applications, we established a nano-flow cytometry assay to detect plasma EVs readily. NSCLC patients demonstrated significantly reduced counts of TTF-1+ EVs and CD151+ EVs in plasma compared to healthy controls (P<0.0001), while SFTPB+ EVs showed no significant difference (P>0.05). Integrated analysis of TTF-1+, CD151+ and SFTPB+ EVs yielded area under the curve (AUC) values of 0.913 and 0.854 in the discovery and validation cohorts, respectively. Thus, while further validation is essential, the newly developed technologies are of great significance for the robust detection of NSCLC biomarkers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Laboratory Investigation
Laboratory Investigation 医学-病理学
CiteScore
8.30
自引率
0.00%
发文量
125
审稿时长
2 months
期刊介绍: Laboratory Investigation is an international journal owned by the United States and Canadian Academy of Pathology. Laboratory Investigation offers prompt publication of high-quality original research in all biomedical disciplines relating to the understanding of human disease and the application of new methods to the diagnosis of disease. Both human and experimental studies are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信